Protocol Ledger

NCT06203600 · Phase II/III · RECRUITING

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Interventional Phase II/III clinical trial protocol NCT06203600 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-24 Enrollment: 224 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06203600
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)224 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06203600
Protocol FieldVerified Registry Value
NCT IdentifierNCT06203600
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment224 participants (ESTIMATED)
Registered Start Date2024-06-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06203600
Hospital Research SiteLocationSite Profile
University of Arkansas for Medical SciencesLittle Rock, AROpen Hospital Dossier ->
Kaiser Permanente-AnaheimAnaheim, CAOpen Hospital Dossier ->
Kaiser Permanente-Baldwin ParkBaldwin Park, CAOpen Hospital Dossier ->
Kaiser Permanente-BellflowerBellflower, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI